Exelixis | EXEL - Betriebsergebnis





Betriebsergebnis Veränderung Datum
Acadia Pharmaceuticals USD 71.72M 33.88M 2026-09
Agios Pharmaceuticals USD -110.55M 527K 2026-06
Akebia Therapeutics USD -5.45M 9.4M 2025-12
Amgen USD 4.68B 65M 2026-09
AstraZeneca USD 4.66B 1.5B 2026-09
Bayer EUR 129M 698M 2026-09
BioMarin Pharmaceutical USD 205.6M 100M 2026-09
Bristol-Myers Squibb USD 255M 44M 2026-09
Cytokinetics USD -167.09M 12.08M 2026-09
Eisai JPY 24.73B 35.04B 2026-06
Eli Lilly USD 12.46B 2.68B 2026-06
Exelixis USD 268.42M 20.01M 2026-09
Genmab DKK 407M 182M 2026-06
Glaxosmithkline GBP 2.13B 166M 2026-09
Incyte USD -707.47M 1.41B 2026-09
Ionis Pharmaceuticals USD -102.29M 15.71M 2026-06
MacroGenics USD -13.85M 19.59M 2026-06
Merck USD 7.33B 6.49B 2026-09
Moderna USD 130M 945M 2026-09
Nektar Therapeutics USD -38.26M 19.17M 2026-03
Neurocrine Biosciences USD 343M 123.1M 2026-09
Novartis USD 5.14B 392M 2026-09
Pfizer USD 662M 5M 2026-09
Puma Biotechnology USD 22.08M 24.26M 2024-09
Sanofi EUR 2.38B 115M 2026-06
Takeda JPY 205.32B 3.9B 2026-09
Ultragenyx Pharmaceutical USD -110M 35M 2026-09
Xencor USD -36.6M 41.26M 2026-06